Technical Analysis for BPTH - Bio-Path Holdings Inc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.68 | 1.71% | 0.05 |
BPTH closed up 1.71 percent on Friday, April 26, 2024, on 7 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 10
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Calm After Storm | Range Contraction | 1.71% | |
New 52 Week Low | Weakness | 1.71% | |
Wide Bands | Range Expansion | 1.71% | |
Oversold Stochastic | Weakness | 1.71% | |
New 52 Week Closing Low | Bearish | 7.63% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 18 hours ago |
Up 5% | about 18 hours ago |
Up 3% | about 18 hours ago |
60 Minute Opening Range Breakout | about 20 hours ago |
Up 2% | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Its lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. The company's other drug candidate, Liposomal Bcl-2, is ready for the clinic where it would be evaluated in lymphoma and solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Solid Tumors Acid Breast Cancer Lymphoma Cell Biology Treatment Of Breast Cancer Therapeutic Products Oncogenes Blood Cancers Apoptosis
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Solid Tumors Acid Breast Cancer Lymphoma Cell Biology Treatment Of Breast Cancer Therapeutic Products Oncogenes Blood Cancers Apoptosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 44.8 |
52 Week Low | 2.35 |
Average Volume | 1,788,485 |
200-Day Moving Average | 9.27 |
50-Day Moving Average | 4.86 |
20-Day Moving Average | 3.51 |
10-Day Moving Average | 3.11 |
Average True Range | 0.75 |
RSI (14) | 35.48 |
ADX | 23.38 |
+DI | 37.65 |
-DI | 21.38 |
Chandelier Exit (Long, 3 ATRs) | 5.41 |
Chandelier Exit (Short, 3 ATRs) | 4.61 |
Upper Bollinger Bands | 4.87 |
Lower Bollinger Band | 2.15 |
Percent B (%b) | 0.2 |
BandWidth | 77.59 |
MACD Line | -0.61 |
MACD Signal Line | -0.61 |
MACD Histogram | 0.0032 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.20 | ||||
Resistance 3 (R3) | 3.19 | 2.99 | 3.12 | ||
Resistance 2 (R2) | 2.99 | 2.86 | 3.00 | 3.09 | |
Resistance 1 (R1) | 2.84 | 2.78 | 2.91 | 2.85 | 3.06 |
Pivot Point | 2.64 | 2.64 | 2.68 | 2.65 | 2.64 |
Support 1 (S1) | 2.49 | 2.51 | 2.57 | 2.51 | 2.30 |
Support 2 (S2) | 2.29 | 2.43 | 2.30 | 2.27 | |
Support 3 (S3) | 2.14 | 2.29 | 2.24 | ||
Support 4 (S4) | 2.16 |